Cytokinetics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

498

Employees498

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

498

Employees498

CYTK Key Statistics

Market cap

7.14B

Market cap7.14B

Price-Earnings ratio

-11.72

Price-Earnings ratio-11.72

Dividend yield

—

Dividend yield—

Average volume

1.81M

Average volume1.81M

High today

$60.77

High today$60.77

Low today

$58.70

Low today$58.70

Open price

$59.51

Open price$59.51

Volume

979.12K

Volume979.12K

52 Week high

$64.13

52 Week high$64.13

52 Week low

$29.31

52 Week low$29.31

CYTK News

Simply Wall St 6h

Cytokinetics: Reassessing Valuation After Lawsuit Reveals Regulatory Risks for Key Heart Drug

Investors in Cytokinetics (CYTK) are reacting after news surfaced of a class action lawsuit claiming the company misrepresented key aspects of its aficamten dru...

TipRanks 2d

Cytokinetics price target raised to $70 from $55 at JPMorgan

JPMorgan raised the firm’s price target on Cytokinetics (CYTK) to $70 from $55 and keeps an Overweight rating on the shares. The firm upped the price target aft...

Simply Wall St 4d

Cytokinetics Faces Lawsuits After FDA Delays Heart Drug Review for REMS Omission – Has the Investment Thesis Shifted?

In October 2025, Cytokinetics disclosed that the FDA extended its review period for the cardiac drug aficamten due to the omission of a required Risk Evaluation...

Analyst ratings

81%

of 21 ratings

Buy

81%

Hold

19%

Sell

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.